36 citations
,
November 2005 in “Forensic Science International” BioPlex-11 improves DNA profiling from telogen hair roots in forensic work.
1 citations
,
February 2025 in “Journal of the Neurological Sciences” Beta-trace protein may help diagnose and predict treatment response in certain nerve disorders.
6 citations
,
May 2006 in “Skinmed” Androgens contribute to common male hair loss; more research needed for hair growth medication.
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
April 2012 in “Informa Healthcare eBooks” AGA is a common hair loss affecting both genders, treated with various therapies to promote regrowth and slow thinning.
April 2024 in “Research Square (Research Square)” A 27-year-old with APS-1 showed improvement in symptoms after treatment.
16 citations
,
July 2018 in “Dermatologic Surgery” iL-PRF treatment improves hair growth for androgenetic alopecia.
May 2025 in “Frontiers in Genetics” A new genetic variant in the LIPH gene causes hair growth issues in a Chinese patient.
June 2023 in “GLOBAL JOURNAL FOR RESEARCH ANALYSIS” PRP is a promising treatment for hair loss.
January 1996 in “Springer eBooks”
January 2025 in “Journal of Materials Chemistry B” A new treatment using special microneedles and a nitric oxide-releasing drug could improve hair growth and be more convenient for people with hair loss.
December 2022 in “Journal of dermatology and skin science” Androgenetic alopecia trials in the U.S. lack racial and ethnic diversity, limiting their applicability.
7 citations
,
March 2020 in “PloS one” α-parvin is necessary for skin and hair growth and for the correct orientation of skin cells.
June 2025 in “International Journal of Molecular Sciences” Targeting EMT and fibrotic remodeling may help treat androgenetic alopecia.
6 citations
,
June 2011 in “British Journal of Dermatology” People with alopecia areata have higher levels of RBP4 protein and antibodies against it.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” New treatments for androgenetic alopecia are emerging, improving options for managing hair loss.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
1 citations
,
August 2022 in “Journal of Drugs in Dermatology” More frequent PRP sessions with shorter intervals improve hair loss treatment.
2 citations
,
June 2024 in “Frontiers in Plant Science” LLPS is crucial for RALF signaling, aiding plant growth and stress resilience.
11 citations
,
January 2010 in “Springer eBooks” January 2014 in “The Journal of Dermatology” Korean adolescents with androgenetic alopecia often have a family history, milder symptoms than adults, and normal hormone levels.
June 2020 in “Journal of Evolution of medical and Dental Sciences” Platelet Rich Plasma (PRP) treatment effectively reduces hair fall and increases hair growth in patients with Androgenetic Alopecia (AGA), but it may cause pain.
January 2024 in “Research Portal Denmark” H+-ATPase is crucial for plant growth and can be influenced by microbial compounds, affecting root hair development.
The treatment showed promising hair regrowth in advanced-stage hair loss.
30 citations
,
November 2013 in “PLOS ONE” Androgen receptor signaling causes early aging of cells important for hair growth by damaging their DNA.
December 2024 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows promise by targeting androgen receptors.
18 citations
,
July 2016 in “Medicine” Wnt/β-catenin and TGF-β pathways affect hair loss, and activating Wnt/β-catenin could be a potential treatment.
January 2009 in “Egyptian Journal of Medical Human Genetics” The study suggests that a specific gene variation and higher gene activity are linked to increased baldness in Egyptian men.
January 2014 in “DOAJ (DOAJ: Directory of Open Access Journals)” Platelet rich plasma may be beneficial for treating hair loss.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.